Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER3 inhibitors

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

ELC Group launches clinical trials offering

Consultancy says service will speed up regulatory submissions

- PMLiVE

Social innovation in pharma

The use of social media by pharma beyond Facebook and Twitter

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

e-Therapeutics raises £40m to support oncology pipeline

Will fund development of ETS2101 for brain cancer and other potential indications

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

India passes clinical trials compensation law

Pharma sponsors will need to pay in cases of trial-related injuries and deaths

- PMLiVE

GSK signs up to AllTrials trial transparency campaign

Will publish formal clinical study reports for all of its medicines

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

PhRMA weighs in on Bad Pharma transparency debate

Says current clinical trial system is "working well"

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links